Additionally, mice transplanted with human leukemia cell lines that express mutated FLT3 show significantly increased survival when ... effect of FLT3 tyrosine kinase inhibitors (TKI) and ARA ...

Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the ...

6: Unmet Needs Addressed by BTKis Brian Koffman, MD, reviews how Bruton tyrosine kinase inhibitors are addressing unmet needs in chronic lymphocytic leukemia, mantle cell lymphoma, and small ...

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions ... A total of 351 patients from six institutions with EGFR-mutant NSCLC developed brain metastases and met inclusion criteria for the ...

The Bruton tyrosine kinase ... free survival in patients with previously-treated CLL. Treatment with Calquence (acalabrutinib) monotherapy significantly improved progression-free survival among ...

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the ...

Zongertinib is an orally-administered, irreversible tyrosine kinase inhibitor that selectively ... patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer and are hopeful about ...

Among previously treated patients with human epidermal growth factor receptor 2 (HER2, ERBB2)–mutant advanced non-small cell ... free survival and duration of response rates were 69% and 73%, ...

Ki67 Proliferation ... analysis comparing overall survival in patients treated with upfront stereotactic radiosurgery (SRS), upfront whole-brain radiotherapy (WBRT), and upfront epidermal growth ...